NeoGenomics Inc. Common Stock vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? NeoGenomics Inc. Common Stock trades at $17.17 (market cap $2.17B), while Vanguard Dividend Appreciation Index Fund ETF trades at $239.98 (market cap $132.40B). The key difference: Vanguard Dividend Appreciation Index Fund ETF is far larger — about 61× NeoGenomics Inc. Common Stock's market cap, and Vanguard Dividend Appreciation Index Fund ETF is more actively traded (893,381 versus 1,615,943). Which is the better fit depends on your goals — on Pluang, investors hold NeoGenomics Inc. Common Stock for 0 Days and Vanguard Dividend Appreciation Index Fund ETF for 134 Days on average.
| NEO | VIG | |
|---|---|---|
Market Cap | $2.17B | $132.40B |
Volume | 1,615,943 | 893,381 |
Sector | Health | — |
52-Week High | $19.91 | $246.61 |
52-Week Low | $7.19 | $210.70 |
Typical Hold Time | 0 Days | 134 Days |
Enterprise Value | $2.47B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VIG trades at $239.71, down slightly by 0.14% on the day, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The ETF focuses on dividend growth stocks with a requirement for 10+ years of consecutive dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent news highlights VIG's 7.5% quarterly dividend increase and its strategic exclusion of high-yield stocks to prioritize sustainable growth.
The outlook for VIG remains positive given its quality dividend growth strategy and historical 10% annual returns, though the current RSI near 90 suggests short-term overbought conditions. Key risks include sensitivity to interest rate changes and slower dividend growth rates. Analyst sentiment is generally favorable, emphasizing VIG's role in long-term wealth building despite its modest yield.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →